Isomorphic Labs' $2.1B Raise Marks Second-Largest AI-Biotech Bet with $3B Pharma Deals

Isomorphic Labs detailed its $2.1 billion Series B on May 13, led by Thrive Capital with Alphabet participation—flagged as the second-largest biotech fundraise behind Altos Labs and following a $600M prior round. Initial May 12 reports covered the DeepMind 2021 spinout's plans to scale its AlphaFold-derived AI drug platform (2x accuracy gains), hire talent, and push toward human trials amid partnerships with Johnson & Johnson, Novartis, and Eli Lilly (up to $3B combined). The capital underscores surging AI-biotech investor appetite, lifting sentiment for Alphabet (GOOG.OQ) and ecosystem plays in compute, chips, and pharma R&D.